Clinical Trial Update: Safety and Immunogenicity of Pvs25-IMX313/Matrix-M1 Vaccine [EARLY_Phase 1]

View source ↗

Summary

An early Phase 1 trial evaluating the safety and immunogenicity of the Pvs25-IMX313/Matrix-M1 malaria vaccine was terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plasmodium Vivax Malaria

Drugs mentioned

• Pvs25-IMX313/Matrix-M1

Snippet

Sponsor: University of Oxford | Conditions: Malaria, Vivax | EARLY_Phase 1 | Status: TERMINATED | Results posted: 2026-01-15